- Home
- BRDG vs SAGE Comparison
BRDG vs SAGE Comparison
Compare BRDG & SAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRDG
- SAGE
- Stock Information
- Founded
- BRDG 2009
- SAGE 2010
- Country
- BRDG United States
- SAGE United States
- Employees
- BRDG N/A
- SAGE N/A
- Industry
- BRDG Investment Managers
- SAGE Biotechnology: Pharmaceutical Preparations
- Sector
- BRDG Finance
- SAGE Health Care
- Exchange
- BRDG Nasdaq
- SAGE Nasdaq
- Market Cap
- BRDG 391.6M
- SAGE 415.0M
- IPO Year
- BRDG 2021
- SAGE 2014
- Fundamental
- Price
- BRDG $10.19
- SAGE $6.61
- Analyst Decision
- BRDG Hold
- SAGE Hold
- Analyst Count
- BRDG 5
- SAGE 19
- Target Price
- BRDG $11.00
- SAGE $9.88
- AVG Volume (30 Days)
- BRDG 225.5K
- SAGE 895.6K
- Earning Date
- BRDG 05-20-2025
- SAGE 04-29-2025
- Dividend Yield
- BRDG 4.51%
- SAGE N/A
- EPS Growth
- BRDG N/A
- SAGE N/A
- EPS
- BRDG N/A
- SAGE N/A
- Revenue
- BRDG $453,729,000.00
- SAGE $47,404,000.00
- Revenue This Year
- BRDG N/A
- SAGE $100.64
- Revenue Next Year
- BRDG $25.81
- SAGE $70.19
- P/E Ratio
- BRDG N/A
- SAGE N/A
- Revenue Growth
- BRDG 61.35
- SAGE N/A
- 52 Week Low
- BRDG $6.56
- SAGE $4.62
- 52 Week High
- BRDG $11.69
- SAGE $14.56
- Technical
- Relative Strength Index (RSI)
- BRDG 62.75
- SAGE 35.95
- Support Level
- BRDG $9.01
- SAGE $6.50
- Resistance Level
- BRDG $9.52
- SAGE $7.63
- Average True Range (ATR)
- BRDG 0.28
- SAGE 0.28
- MACD
- BRDG 0.09
- SAGE -0.09
- Stochastic Oscillator
- BRDG 92.75
- SAGE 7.26
About BRDG Bridge Investment Group Holdings Inc.
Bridge Investment Group Holdings Inc is a vertically integrated investment manager, diversified across specialized asset classes. The company combines its operating platform with dedicated teams of investment professionals focused on various specialized and synergistic investment platforms, including real estate, credit, renewable energy, and secondaries strategies. Its products and vertically integrated structure allow it to capture new market opportunities and serve investors with various investment objectives. The Company operates as one business, a fully integrated real estate investment manager.
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.